导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.83% | 49/108 |
| 近一周 | -3.71% | 69/119 |
| 近一月 | -0.82% | 7/121 |
| 近一季 | -13.67% | 81/117 |
| 近半年 | -7.69% | 62/111 |
| 近一年 | -10.32% | 51/99 |
| 近两年 | 43.20% | 55/94 |
| 近三年 | 6.06% | 63/74 |
| 成立以来 | 61.50% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.81% 52/109 |
23.81% 33/119 |
- - |
- - |
| 2025 | 35.34% 42/108 |
13.63% 29/97 |
12.90% 42/99 |
18.75% 40/104 |
-11.17% 76/108 |
| 2024 | -17.77% 93/97 |
-15.07% 89/89 |
10.92% 3/94 |
-4.18% 89/97 |
-8.90% 85/97 |
| 2023 | -12.03% 46/93 |
-2.31% 53/73 |
-8.98% 51/77 |
-2.06% 24/82 |
1.01% 42/93 |
| 2022 | -13.57% 14/71 |
-6.52% 4/58 |
8.49% 21/62 |
-13.62% 31/68 |
-1.34% 55/71 |
| 2021 | -16.24% 32/58 |
7.33% 41/312 |
1.51% 194/328 |
-15.09% 271/358 |
-9.47% 44/58 |
| 2020 | 12.64% 26/38 |
-0.06% 27/280 |
11.92% 151/295 |
2.23% 141/299 |
-1.50% 269/305 |
| 2019 | 23.73% 17/30 |
10.84% 107/258 |
0.80% 151/268 |
-3.31% 211/253 |
14.54% 16/266 |
| 2018 | -22.03% 18/28 |
- - |
- - |
- - |
-10.93% 123/241 |
| 2017 | 54.16% 1/20 |
- - |
- - |
- - |
- - |
| 2016 | -3.81% 15/17 |
- - |
- - |
- - |
- - |
| 2015 | -2.25% 5/16 |
- - |
- - |
- - |
- - |
| 2014 | 0.70% 58/99 |
- - |
- - |
- - |
- - |
| 2013 | 19.50% 14/70 |
- - |
- - |
- - |
- - |
| 2012 | 25.97% 1/51 |
- - |
- - |
- - |
- - |
| 2011 | -22.50% 18/27 |
- - |
- - |
- - |
- - |
| 2010 | -3.17% 9/9 |
- - |
- - |
- - |
- - |
| 2009 | 54.08% 7/9 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 摩根中国生物医药混合(QDII)A | 1.4779 | 18.54% |
| 南方港股医药行业混合发起(QDII)A | 1.3423 | 18.34% |
| 摩根中国生物医药混合(QDII)C | 1.4554 | 17.49% |
| 南方港股医药行业混合发起(QDII)C | 1.2936 | 15.12% |
| 东方红医疗创新混合(QDII)A | 0.8769 | 15.09% |
| 东方红医疗创新混合(QDII)C | 0.8725 | 14.94% |
| 富国医药精选混合(QDII)A | 0.9730 | 9.63% |
| 长城港股医疗保健精选混合发起(QDII)C | 0.7545 | 8.73% |
| 长城港股医疗保健精选混合发起(QDII)A | 0.7593 | 8.70% |
| 富国医药精选混合(QDII)C | 0.9680 | 8.18% |
| 华宝海外中国成长混合 VS. 建信新兴市场混合(QDII)A(539002) |